AVE 5026: Clinical Trials

2 trials of AVE 5026, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 completed, 1 terminated. 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 22Completed 1, Terminated 1

Follow AVE 5026: new trials by email Literature Review of AVE 5026 trials Research Report on AVE 5026

Trials (filtered) newest first · largest first

All 2 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study of AVE5026 at Weight-adjusted Doses in Children With a Central Venous Line
Semuloparin sodium - Thrombosis Prophylaxis (Risk of Thrombosis Due to Central Venous Line (CVL)
Phase 2TerminatedSanofi22012-05-012016-05-03
Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Knee Replacement Surgery
Semuloparin sodium, Placebo (for Enoxaparin sodium), Enoxaparin sodium - Venous Thromboembolism
Phase 2CompletedSanofi7052006-05-012013-01-15

Conditions studied

Thrombosis (1)  ·  Venous Thromboembolism (1)  ·  Venous Thrombosis (1)

Sponsors

Sanofi (2)

Countries

Argentina (1)  ·  Bulgaria (1)  ·  Chile (1)  ·  Colombia (1)  ·  Denmark (1)  ·  Finland (1)  ·  Greece (1)  ·  Hungary (1)  ·  Malaysia (1)  ·  Mexico (1)  ·  Norway (1)  ·  Philippines (1)  ·  Poland (1)  ·  Portugal (1)  ·  Romania (1)

Results publications

PMID 19187076

NIH funding

2005 (1)